Barrett’s oesophagus: Better left alone?

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 6, 2001, Pages 627-630

  Lambert, René ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Adenocarcinoma; Barrett s oesophagus; Endoscopy; Surveillance

Indexed keywords

BARRETT ESOPHAGUS; CANCER RISK; DYSPLASIA; ENDOSCOPY; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0034975671     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200106000-00002     Document Type: Article

References (41)

1. Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1998; 94: 2043-2053.
2. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: Is it cost effective? Am J Gastroenterol 2000; 95: 2086-2093.
3. Streitz JM, Ellis FH, Tilden RL, Erickson RV. Endoscopic surveillance of Barrett’s esophagus: A cost effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998; 93: 911-915.
4. van der Burgh A, Dees J, Hop WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus. Gut 1996; 39: 5-8.
5. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 2000; 119: 333-338.
6. Tytgat GNJ. Does endoscopic surveillance in esophageal columnar metaplasia (Barrett’s esophagus) have any value? Endoscopy 1995; 27: 19-26.
7. Gudlaugsdottir S, Blankenstein M, Dees J, Wilson JHP. A majority of patients with Barrett’s oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol, 2001; 13: 639-645.
8. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456.
9. Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 81-92.
10. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51: 24-29.
11. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adult. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-211.
12. Armstrong RW, Borman B. Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978-1992. Int J Epidemiol 1996; 25: 941-947.
13. Botterweck AAM, Shouten LJ, Volovics A, Dorant E, van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 645-654.
14. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett’s esophagus: A population-based study. Am J Gastroenterol 1999; 94: 86-91.
15. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
16. Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway 1958-1992: Incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997; 71: 340-344.
17. Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ, Thursfield V. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998; 13: 356-362.
18. El Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-333.
19. McKinney A, Sharp L, Macfarlane GJ, Muir CS. Oesophageal and gastric cancer in Scotland 1960-90. Br J Cancer 1995; 71: 411-415.
20. Moller H. Incidence of cancer of oesophagus, cardia and stomach in Denmark. Eur J Cancer Prev 1992; 1: 159-164.
21. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62: 440-443.
22. Thomas RJ, Lade S, Giles GG, Thursfield V. Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust NZ J Surg 1996; 66: 271-275.
23. Zheng T, Mayne ST, Holford TR, Boyle P, Liu W, Chen Y. et al. Time trend and age-period cohort effects on incidence of esophageal cancer in Connecticut, 1935-89. Cancer Causes Control 1992; 3: 481-492.
24. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. In: Cancer Incidence in Five Continents. Vol. VII (IARC Scientific Publications, No. 143). Lyon: IARC; 1997. pp. 1-1240.
25. Ormsby AH, Vaezi MF, Richter JE, Goldblum JR, Rice TW, Falk G. et al. Cytokeratin immunoreactivity patterns in the diagnosis of short segment Barrett’s esophagus. Gastroenterology 2000; 119: 683-690.
26. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 1999; 117: 218-228.
27. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
28. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000; 133: 165-175.
29. Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA. et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998; 7: 749-756.
30. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH. et al. Tobacco, alcohol and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89: 1277-1284.
31. Lagergren J, Bergstrom R, Adami HO, Nyren O. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut 2000; 47: 26-29.
32. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-890.
33. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: Adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995; 4: 85-92.
34. Cheng KK, Sharp L, McKinney PA, Logan RFA, Chilvers CED, Cook-Mozaffari P. et al. A case-control study of oesophageal adenocarcinoma in women: A preventable disease. Brit J Cancer 2000; 83: 127-132.
35. Ekstrom AM, Signorello MB, Hansson LE, Bergstrom R, Lindgren A, Nyren O. Evaluating gastric cancer misclassification: A potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst 1999; 91: 786-790.
36. S.E.E.R. Cancer incidence use database,1973-1995. 1998; CD-Rom.
37. Bacon F. The Advancement of Learning. London: Henrie Tomes; 1605.
38. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989; 81: 107-115.
39. Spechler SJ. Barrett’s esophagus: An overrated cancer risk factor. Gastroenterology 2000; 119: 587-589.
40. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS. et al. Effect of segment length on risk for neoplastic progression in patients with Barrett’s esophagus. Ann Intern Med 2000; 132: 612-620.
41. Hirota WK, Loughney TM, Lazas DJ, Maydonowitch CL, Rholl V, Wong RKH. Specialized intestinal metaplasia, dysplasia and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 227-285.